Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil
AUTOR(ES)
Biot, Stephanie Del Rio Navarrete, Franco, Joanna Pimenta de Araujo, Lima, Ricardo Barbosa, Pereira, Henrique Novo Costa, Marques, Luiz Paulo José, Martins, Carlos José
FONTE
An. Bras. Dermatol.
DATA DE PUBLICAÇÃO
2014-12
RESUMO
The main treatment for pemphigus vulgaris are systemic corticosteroids and immunosuppressive agents, but due to adverse reactions and therapeutic failure, new drugs such as rituximab and mycophenolate mofetil have been used. In this case report are described two cases of severe pemphigus vulgaris refractory to various treatments, with resolution after use of rituximab and mycophenolate mofetil, associated with corticosteroids. A higher-than-usual dose of rituximab was employed, without the occurrence of serious adverse reactions. Mycophenolate mofetil was added as adjunctive therapy due to lack of response to azathioprine.
Documentos Relacionados
- Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series
- RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection.
- Qualitative analysis of the deposit of collagen in bladder suture of rats treated with tacrolimus combined with mycophenolate-mofetil
- Treatment of Guillain–Barré syndrome with mycophenolate mofetil: a pilot study
- Induction of remission in active anti‐neutrophil cytoplasmic antibody‐associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide
